Follow us on Twitter
twitter icon@FreshPatents


Diabetes patents

      

This page is updated frequently with new Diabetes-related patent applications.

SALE: 520+ Diabetes-related patent PDFs



 Pairing and synchronizing a mobile phone application with a handheld glucose meter patent thumbnailPairing and synchronizing a mobile phone application with a handheld glucose meter
A diabetes management system includes a handheld medical device, a mobile computing device, and a diabetes management application. The handheld medical device is configured to determine, in response to a port receiving a test strip, whether an auto-send feature is enabled on the handheld medical device, determine whether the handheld medical device is paired with a mobile computing device, and selectively instruct a wireless transceiver to establish a wireless connection and communicate a glucose measurement and identifying information to the mobile computing device.
Roche Diabetes Care, Inc.


 Condensed heterocyclic compound patent thumbnailCondensed heterocyclic compound
The present invention relates to a condensed heterocyclic compound that has an enteropeptidase inhibitory effect and is useful in the treatment or prevention of obesity, diabetes mellitus, or the like, and a medicament containing the same. Specifically, the present invention relates to a compound represented by the following formula (i) or a salt thereof, and a medicament containing the same [in the formula, each symbol is as defined in the specification]..
Takeda Pharmaceutical Company Limited


 Biaryl derivative as gpr120 agonist patent thumbnailBiaryl derivative as gpr120 agonist
The present invention relates to a biaryl derivative expressed by the chemical formula 1, a method for producing the biaryl derivative, a pharmaceutical composition comprising same, and use of same, the biaryl derivative expressed by the chemical formula 1, as a gpr120 agonist, promoting glp-1 generation in the gastro-intestinal tract, reducing insulin resistance in the liver, muscles and the like from anti-inflammatory activity in the macrophage, pancreatic cells and the like, and allowing effective use in prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.. .
Lg Chem, Ltd.


 Risk-based control-to-range patent thumbnailRisk-based control-to-range
Methods and systems are disclosed for determining a basal rate adjustment of insulin based on risk associated with a glucose state of a person with diabetes. A method may include detecting a glucose state of the person based on a received glucose measurement signal and determining a current risk metric associated with the detected glucose state.
Roche Diabetes Care, Inc.


 Control-to-range aggressiveness patent thumbnailControl-to-range aggressiveness
A method and system of determining a basal rate adjustment of insulin in a continuous glucose monitoring system of a person with diabetes is provided. The method includes receiving, by at least one computing device, a signal representative of at least one glucose measurement; detecting, by the at least one computing device, a glucose state of the person based on the signal, the detected glucose state including a glucose level of the person and a rate of change of the glucose level; determining, by the at least one computing device, a current risk metric, the current risk metric indicating a risk of at least one of a hypoglycemic condition and a hyperglycemic condition of the person; and calculating, by the at least one computing device, an adjustment to a basal rate of a therapy delivery device based on the current risk metric and a control-to-range algorithm comprising at least one aggressiveness parameter..
Roche Diabetes Care, Inc.


 Control-to-range failsafes patent thumbnailControl-to-range failsafes
Methods and systems are disclosed for determining a basal rate adjustment of insulin in a continuous glucose monitoring system of a person with diabetes. A method may include receiving, by at least one computing device, a signal representative of at least one glucose measurement and detecting, by the at least one computing device, a glucose state of the person based on the signal, the detected glucose state including a glucose level of the person and a rate of change of the glucose level.
Roche Diabetes Care, Inc.


 Method for ameliorating and abating symptoms resulting from rheumatoid arthritis, fibromyalgia, and chronic pain of unknown origin patent thumbnailMethod for ameliorating and abating symptoms resulting from rheumatoid arthritis, fibromyalgia, and chronic pain of unknown origin
The present invention provides a composition and method for treating diseases associated with demyelination of the nerves, such as als, ra, tremors/parkinson's disease, and ms, alzheimer's disease, als, guillain-barre syndrome, atherosclerosis, schizophrenia, tremors/parkinson's disease, senile dementia, muscular dystrophy, attention deficit disorder, attention deficit hyperactivity disorder, complex regional pain syndrome, diabetes, neuropathic pain, spider arthritis west nile virus,, fibromyalgia, shingles, gout, migraine headaches, post polio syndrome, central virus deafness, asthma, chronic pain of unknown origin and hepatitis c and for treating non-viral based cancers. By administering measured doses of an immunity-provoking agent and a bacterial antigen activator, patients suffering from als, ra, ms, tremors/parkinson's disease, and prostate cancer and others realized immediate beneficial results with no side effects..
Honor C.w. M.d., Llc


 Compositions and methods for decreasing blood glucagon levels patent thumbnailCompositions and methods for decreasing blood glucagon levels
Disclosed are improved compositions and methods for decreasing blood glucagon levels. As disclosed herein, l-glutamine is a selective stimulator of α-cell proliferation generated when glucagon signaling is interrupted.
Vanderbilt University


 Use of helminthostachys zeylanica, ugonins or flavone-based compounds for the treatment or prevention of metabolic diseases patent thumbnailUse of helminthostachys zeylanica, ugonins or flavone-based compounds for the treatment or prevention of metabolic diseases
Disclosed is a use of helminthostachys zeylanica, ugonins or compounds of formula (i) for the treatment or prevention of metabolic diseases comprising at least one selected from metabolic syndrome, excessive lipid accumulation, obesity, overweight, fatty liver, hepatic steatosis, hepatitis, cirrhosis, liver cancer, dyslipidemia, hyperlipidemia, hypertriglyceridemia, hyperlipoproteinemia, hypercholesterolemia, cardiovascular disease, hyperglycemia, hyperinsulinemia, diabetes mellitus type 2, insulin resistance, insulin disorder, impaired glucose tolerance and a combination thereof.. .
National Research Institute Of Chinese Medicine, Ministry Of Health And Welfare


 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes patent thumbnailBeta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-iv enzyme (“dp-iv inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-iv enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-iv enzyme is involved..
Merck Sharp & Dohme Corp.


Method of treating liver fibrosis

A method of treating liver fibrosis with ccr2 antagonists is provided. The liver fibrosis may be associated with non-alcoholic steatohepatitis (nash), non-alcoholic fatty liver disease (nafld), emerging cirrhosis, non-cirrhotic hepatic fibrosis, type 2 diabetes mellitus (t2dm) or metabolic syndrome (ms)..
Chemocentryx, Inc.

Compositions containing omega-3 oil and uses thereof

The invention provides pharmaceutical compositions containing omega-3 oil and a non-hydrophilic co-solvent that have an increased absorption rate. The pharmaceutical compositions may further contain one or more pharmaceutical organic molecules.
Maine Natural Health Company, Inc.

System for adjusting pressure locally on the skin and subcutaneous tissue

The invention relates to a system for adjusting pressure locally acting on the skin. Said system includes a set of adjacent modules distributed so as to form a layer.
Ecole Polytechnique Federale De Lausanne (epfl)

Electrode assembly

The present invention relates to an electrode assembly (eg a nanoelectrode assembly), to an electrochemical glucose biosensor comprising the electrode assembly and to an apparatus for combating (eg management of) diabetes mellitus which comprises the electrochemical glucose biosensor.. .
Nanoflex Limited

System and assessing quantities or sizes of lipoprotein particles from lipoprotein particle compositions

This application discloses methods for assessing quantities of spherical or substantially spherical lipoprotein particles or portions thereof present in a biological sample based on the measurement of free cholesterol and/or phospholipid content in the lipoprotein particles. Methods of treating a subject at increased risk for cardiovascular disease and/or cardiodiabetes are also disclosed..
True Health Ip Llc

Hepatocyte based insulin gene therapy for diabetes

A method and vectors for controlling blood glucose levels in a mammal are disclosed. In one embodiment, the method comprises the steps of: treating the hepatocyte cells of a patient with a first, second or third vector, wherein the first vector comprises a promoter enhancer, glucose inducible regulatory elements, a liver-specific promoter, a gene encoding human insulin with modified peptidase and an albumin 3′utr and lacks an hgh intron, wherein the second vector comprises an hgh intron, glucose inducible regulatory elements, a liver-specific promoter, a gene encoding human insulin with modified peptidase site and an albumin 3′utr and lacks a promoter enhancer, wherein the third vector comprises an hgh intron, glucose inducible regulatory elements, a liver-specific promoter, a gene encoding human insulin with modified peptidase site, an albumin 3′utr and a promoter enhancer and observing the patient's insulin levels, wherein the patient's insulin levels are controlled..
Wisconsin Alumni Research Foundation

Use of microrna precursors as drugs for inducing cd34-positive adult stem cell expansion

This invention generally relates to a composition and its production method useful for developing drugs/vaccines and/or therapies against a variety of degenerative diseases in humans. Particularly, the present invention teaches the essential steps of production and purification processes necessary for producing small hairpin-like rna (shrna) compositions, such as microrna precursors (pre-mirna) and short interfering rnas (sirna), which are useful for treating human ageing related diseases, such as, but not limited, alzheimer's diseases, parkinson's diseases, osteoporosis, diabetes, and cancers.

Antibody therapy for modulating function of intestinal receptors and methods of treating diabetes and obesity

The present invention provides pharmaceutical compositions formulated for direct delivery to the gi tract of a patient comprising an antibody specific for a target apical intestinal receptor. The present invention further provides methods of treating diseases and conditions in a patient comprising administering directly to the gi tract of the patient, compositions of the present invention wherein modulation of the target apical intestinal receptor by the antibody treats the condition..
Circle 33 Llc

Methods and compositions to treat type-1 and type-2 diabetes

The present disclosure is directed to novel methods of treating type-1 or type-2 diabetes by inactivating tlr2 and tlr4 genes together in cells capable of producing insulin and/or regenerating β cells, and providing the cells to a subject in need thereof.. .
Cornell University

Pyrazino[2,3-b]pyrazine mtor kinase inhibitors for oncology indications and diseases associated with the mtor/pi3k/akt pathway

Wherein r1-r4 are as defined herein, compositions comprising an effective amount of a heteroaryl compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a heteroaryl compound to a patient in need thereof.. .

A multi-state ratchet mechanism for drug injection devices

The present invention relates in a first aspect to a multi-state ratchet mechanism for a drug injection device. The multi-state ratchet mechanism comprises a ratchet gear member and a cooperating ratchet pawl member.
Novo Nordisk A/s

Cell-based composition and use thereof for treatment of diabetes and associated metabolic disorders and for amelioration of insulin resistance in pre-diabetes

The present invention relates to a cell-based composition comprising a suspension of mesenchymal stem cells in crystalloid with a cellular concentration from 0.01 million to 3.0 million cells/ml. The cell-based composition is used in a form of medicament for treatment of diabetes and its associated metabolic disorders and complications..
Cytopeutics Sdn. Bhd.

Non-reducing end unsaturated mannuronic acid oligosaccharides and compositions containing same as active ingredient

Disclosed is a non-reducing end unsaturated mannuronic acid oligosaccharide having a molecular weight of 100-3000 da, which is obtained by lysing polymannuronate as a substrate with alginate lyase, and provided are: a non-reducing end unsaturated mannuronic acid oligosaccharide; and pharmaceutical compositions for alleviating, preventing, or treating obesity, diabetes, and climacteric syndrome, and probiotics for promoting intestinal beneficial bacteria, the compositions and probiotics containing, as an active ingredient, the non-reducing end unsaturated mannuronic acid oligosaccharide, so that the antiobesity and antidiabetic effects, estrogen activity, and intestinal microflora controlling effect of the non-reducing end unsaturated mannuronic acid oligosaccharides are remarkably excellent as compared with non-reducing end saturated mannuronic acid oligosaccharides.. .
Industry Foundation Of Chonnam National University

Bromocriptine formulations

The present application describes pharmaceutical formulations of bromocriptine mesylate and methods of manufacturing and using such formulations. The formulations are useful for improving glycemic control in the treatment of type 2 diabetes..
Veroscience Llc

Alpha-cell re-generation combined with conversion to beta cells

The present invention relates to methods of generating a population of beta cells from a population of alpha cells, by contacting said population of alpha cells with gaba or a gaba receptor agonist, in combination with a monoclonal glucagon neutralizing antibody or other alpha cell mass regulating compounds, for an improved diabetes therapy.. .
Universite De Nice Sophia Antipolis-grand ChÂteau

Methods for identifying responders to dopaminergic neuronal enhancing therapies for the treatment of elevated heart rate and metabolic or cardiovascular conditions

Methods for identifying responders to agents that increase brain dopaminergic neuronal activity for the treatment of metabolic and cardiovascular disease and for treating elevated heart rate and metabolic disease or dysglycemia in subjects with type 2 diabetes.. .
Veroscience Llc

Anti-acth antibodies and use thereof

The present invention is directed to antibodies and fragments thereof having binding specificity for acth. Another embodiment of this invention relates to the antibodies binding fragments thereof described herein, comprising the sequences of the vh, vl and/or cdr polypeptides described herein, and the polynucleotides encoding them.
Alder Biopharmaceuticals, Inc.

Thienopyranones as kinase and epigenetic inhibitors

The invention relates to methods of treating diseases including but not limited to, cancer, non-cancer proliferative disease, sepsis, autoimmune disease, viral infaction, atheroscleosis, type 1 or 2 diabetes, obesity, inflammatory disease, or myc-depenent disorder including by modulating biological processes by the inhibition of pi3 kinase and/or bromodomain protein binding to substrates comprising the administration of a compound(s) of formula i-ix (or pharmaceutically acceptable salts thereof) as defined herein.. .
Signalrx Pharmaceuticals, Inc.

New pyrazolopyrimidine derivatives as nik inhibitors

The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of nf-κb-inducing kinase (nik—also known as map3k14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders..
Janssen Pharmaceutical Nv

New compounds as nik inhibitors

The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of nf-κb-inducing kinase (nik—also known as map3k14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders..
Janssen Pharmaceutica Nv

New pyrazole derivatives as nik inhibitors

The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of nf-κb-inducing kinase (nik—also known as map3k14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders..
Janssen Pharmaceutica Nv

Compounds and methods for activating the apoptotic arm of the unfolded protein response

N-substituted sulfonylphenyl-5-nitrofuranyl-2-carboxamide derived compounds, which selectively activate the apoptotic, but not the adaptive arm, of the unfolded protein response are provides as is their use in the treatment of diseases such as diabetes, alzheimer's, parkinson's, hemophilia, lysosomal storage diseases and cancer.. .
Sanford-burnham Medical Research Institute

Pyrazole compounds

This invention relates to pyrazole compounds or pharmaceutically acceptable salts thereof. Compounds of this invention are inhibitors of methionine aminopeptidase 2 (metap2) and dipeptidyl peptidase-4 (dpp-4).
Eli Lilly And Company

Novel mitochondrial uncouplers for treatment of metabolic diseases and cancer

The present disclosure relates to benzamide compounds, prodrugs of the compounds, pharmaceutical compositions containing the compounds and/or the prodrugs and methods of using the compounds, prodrugs and pharmaceutical compositions in the treatment of diseases related to lipid metabolism including diabetes, non-alcholic fatty liver disease (nafld), non-alcholic steathohepatitis (nash), diseases caused by abnormal cell proliferation including cancer, psoriasis, and infectious diseases.. .

Novel approach to treatment of hyperglycemia using a nanoparticle encapsulated peptide

The present invention relates to compositions and methods for treating or preventing hyperglycemia and diseases associated with hyperglycemia. In certain embodiments, the composition comprises a peptide having the amino acid sequence krscyk wherein the peptide consists of d-amino acids is useful in treating or preventing diabetes.
University Of Rochester

Methods for treating and/or limiting development of diabetes

The present invention provides methods for identifying candidate compounds for limiting development of and/or treating diabetes, and methods for limiting development of and/or treating diabetes.. .
Biocrine Ab

Pharmaceutical composition, methods for treating and uses thereof

The present invention relates to certain sglt-2 inhibitors for treating, preventing, protecting against and/or delaying the progression of chronic kidney disease in patients, for example patients with prediabetes, type 1 or type 2 diabetes mellitus.. .
Boehringer Ingelheim International Gmbh

Salts and compositions useful for treating disease

The invention provides a combination or salt of lipoic acid and a compound of formula (i): the combinations and salts are useful for treating diabetes.. .
Regents Of The University Of Minnesota

Therapeutic compound and its application in repairing diabetes-related cardiac injuries

The present invention is related to a therapeutic compound and its application in repairing diabetes-related cardiac injuries, particularly with providing a therapeutic composition containing the epigallocatechin gallate (egcg) of green tea and the adipose-derived stem cells. The epigallocatechin gallate (egcg) of green tea can enhance the ability of the adipose-derived stem cells to repaired damaged tissue.
Numen Biotech Co., Ltd

Method of treating hyperglycemia

Disclosed herein are methods for treating conditions and/or disorders related to hyperglycemia. Such conditions and/or disorders related to hyperglycemia include, but are not limited to, type i, ii diabetes mellitus, gestational diabetes, other forms diabetes, and disorders related thereto.
Center Laboratories, Inc.

Methods and systems for treating diabetes and related diseases and disorders

Systems, device and methods treat target tissue to provide a therapeutic benefit to the patient. A tissue treatment device comprises a tissue treatment element constructed and arranged to treat target tissue, such as duodenal mucosa tissue..
Fractyl Laboratories, Inc.

Method for treating diabetes and other glucose regulation disorders using stem cells

Various embodiments of the invention provide methods of treating diabetes and other glucose regulation disorders. In one embodiment, the method comprises removing l-cells from a donor, obtaining stem cells from a patient, and culturing the l-cells in the presence of the stem cells under conditions such that the stem cells differentiate into stem cell-derived l-cells (scdlc).
Incube Labs, Llc

Composition to induce bone marrow stem cell mobilization

A pharmaceutical composition to induce bone marrow stem cell mobilization from the bone marrow to peripheral blood in patients suffering from pathological conditions, such as diabetes, or subjected to treatments that impair cell mobilization, or in patients suffering from the so called “poor mobilizer” condition, includes at least one therapeutic agent that inhibits production and/or action of the human cytokine oncostatin m (osm), a macrophage derived factor, that prevents mobilization of stem cells.. .
Universitá Degli Studi Di Padova

Omefibrates for treating dyslipidemia and cardiovascular disease

The present invention relates to the fibric acid derivatives of omega-3 fatty acids and their use in treating type2 diabetes, obesity, hypertriglyceridemia, cardiovascular diseases, metabolic syndrome, cancer, alzheimer's disease; and their use for modulating activity of peroxisome proliferator-activated receptors (ppars).. .
Jiva Pharma, Inc.

Satiation peptides for weight loss and altered taste sensitivity

The present application provides methods and compositions for aav-mediated delivery of pyy and glucagon-like peptide 1 or an analog thereof (e.g., exendin-4) to a subject (e.g., the saliva of a subject). In some embodiments, compositions and methods for topical delivery of ex-4 and pyy peptides also are provided.
University Of Florida Research Foundation, Inc.

Use of caspase-2 inhibitors to treat and prevent the metabolic syndrome

Methods and compositions for treatment of obesity, insulin resistance, hyperinsulinemia, type 2 diabetes mellitus, dyslipidemia, and nonalcoholic fatty liver disease are discloses. The methods and compositions relate to inhibition of caspase-2..
Duke University

Treatment of mild and moderate alzheimer's disease

The present invention relates to methods of treatment using [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl}-phenoxy)-propyl]-diethyl amine (“compound i”) or a pharmaceutically acceptable salt thereof. In various embodiments, the methods of treatment include treatment of mild-to-moderate dementia of alzheimer's type, diabetes, insomnia, and other indications.
Vtv Therapeutics Llc

Methods for detecting gestational diabetes mellitus

The present invention relates to methods for diagnosing gestational diabetes mellitus (gdm) in a pregnant female.. .
Kantonsspital Aarau Ag

Methods and compositions for diagnosis and management of diabetes and metabolic syndrome

Described herein are assays, methods, and devices for diagnosing/prognosing diabetes, metabolic syndrome, pre-diabetic state and/or the early-onset of diabetes in a subject. The assays, methods, and devices described herein can be configured to detect one or more long-coding rnas in a sample from a subject..
The U.s. Government As Represented By The Departme Nt Of Veterans Affairs Office Of General Counsel

Alpha/beta-polypeptide analogs of glucagon-like peptide 1

Described herein are peptide analogs of glucagon-like peptide 1 (glp-1) that retain agonist activity, but are more resistant to proteolytic degradation than native glp-1. In the analogs, at least one α-amino acid found in the native glp-1 is replaced with a β-amino acid residue, which may or may not be cyclically constrained.
President And Fellows Of Harvard College

Derivatives of 2-(1,2,4-triazol-3-ylsulfanyl)-n-1,3,4-thiadiazol-2-yl acetamide which are useful for the treatment of inter alia diabetes

Disclosed are compounds, pharmaceutical compositions and methods for modulating aquaporin 9.. .
Apoglyx Ab

Novel heterocyclic derivatives and their use in the treatment of neurological disorders

In which all of the variables are as defined in the specification, pharmaceutical compositions thereof, combinations thereof, and their use as medicaments, particularly for the treatment of alzheimer's disease or diabetes via inhibition of bace-1 or bace-2.. .

Novel pentadienoyl piperidine derivative and use thereof

The present invention relates to a novel pentadienoyl piperidine derivative, a pharmaceutical composition containing the same for prevention or treatment of metabolic diseases, and a functional food composition using the same for improvement or relief of metabolic diseases. The pentadienoyl piperidine derivative of the present invention inhibits the differentiation of preadipocytes, reduces body weight, visceral fat, blood lipid levels, and blood glucose levels, improves a blood liver function index, and suppresses metabolic inflammation responses.
Snu R&db Foundation

Synergistic compositions

The present invention describes a synergistic composition comprising of one or more statins, or one or more dipeptidyl peptidase iv (dpp iv) inhibitor or one or more biguanide antihyperglycaemic agent and a ppar agonist of formula (1a) for the treatment of diabetes, especially non-insulin dependent diabetes or type 2 diabetes and conditions associated with diabetes mellitus and to compositions suitable for use in such method. The invention also describes the preparation of such compositions.
Cadila Healthcare Limited

Dosing regimen

The present invention relates to a long acting insulin analogue for use in reducing the risk of hypoglycaemia in a patient suffering from diabetes and requiring high amounts of delivered insulin, wherein the long acting insulin analogue is administered to said patient and in an amount of greater than 80 u/administration.. .
Novo Nordisk A/s

A dietary fibre composition

The invention provides a composition comprising glucomannan, carrageenan, xanthan gum and a monovalent or divalent cation salt. The composition is suitable for use in managing weight, combating obesity, combating metabolic syndrome, promoting satiety, reducing appetite, combating diabetes, lowering blood cholesterol, lowering blood pressure, reducing postpranial glycaemia, or increasing insulin sensitivity..
Inqpharm Group Sdn Bhd

Aldose reductase inhibitors and uses thereof

The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, infections of the skin, peripheral vascular disease, stroke, and the like..
The Trustees Of Columbia University In The City Of New York

Composition

The present invention relates to compositions for use and formulation as weight management products and in particular fermented dairy foodstuffs. The compositions generally comprise two or more of the following components: a) a microbiome modifying component; b) a satiety modifying component; and c) a metabolic modifying 5 component and at least one of the following: d) streptococcus thermophilus cbs 139100 and lactobacillus delbrueckii subsp.
Optibiotix Limited

Integrated medicament delivery device for use with continuous analyte sensor

An integrated system for the monitoring and treating diabetes is provided, including an integrated receiver/hand-held medicament injection pen, including electronics, for use with a continuous glucose sensor. In some embodiments, the receiver is configured to receive continuous glucose sensor data, to calculate a medicament therapy (e.g., via the integrated system electronics) and to automatically set a bolus dose of the integrated hand-held medicament injection pen, whereby the user can manually inject the bolus dose of medicament into the host.

Optical biomodule for detection of diseases at an early onset

Additionally, chemical compositions and targeted, passive and programmable/active delivery (in near real-time/real-time) of bioactive compounds and/or bioactive molecules for lowering the risks of alzheimer's, cardiovascular and type-2 diabetes diseases are disclosed.. .

Method for determining risk of diabetes

A method of determining risk of diabetes is provided. In one embodiment, the method comprises: a) measuring the levels of a plurality of biomarkers in a blood samples obtained from a patient, wherein the plurality of biomarkers comprises at least five of the following biomarkers: glucose, adiponectin, crp, il2ra, ferritin, insulin and hba1c; b) calculating a diabetes risk score for the patients using the levels and, optionally, patient age and/or gender.

Methods of treating acute myeloid leukemia with antibodies to bone marrow stromal antigen 1

The invention provides antibodies which bind to the adp-ribosyl cyclase 2. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided.

System and relieving high blood sugar factor of diabetes

A system and method for relieving high blood sugar factor of diabetes includes an energy wave generator with an energy wave's frequency control mode. The energy wave's frequency control mode includes multiple controls for controlling and generating energy waves with corresponding energy densities to effect on diabetic patient's body, so as to reduce and eliminate the high blood sugar factors of the diabetic patient..

Compositions and methods for treatment of prediabetes

The invention provides compositions and methods to treat prediabetes. In particular, the inventor has discovered that particular combinations of diverse types of antioxidants have synergistic and surprising effects for use against prediabetes.

Methods and compositions for in vivo induction of pancreatic beta cell formation

Embodiments of the invention stimulate three levels of beta cell physiology: (i) glucose metabolism, (ii) membrane receptor function, and (iii) transcriptional factors that result in the in vivo formation of beta cells in the pancreas for the purpose of treating diabetes. In certain aspects, the methods include the integration of three levels of cellular physiology: metabolism, membrane receptor function, and gene transcription.

Use of nitrite salts in chronic ischemia

Methods of treating a subject who has chronic tissue ischemia are disclosed. The methods can include administering to the subject a pharmaceutical composition comprising inorganic nitrite or a pharmaceutically acceptable salt thereof, for a time and in an amount sufficient to result in blood vessel growth in the ischemic tissue.

Dpp iv inhibitor formulations

The present invention relates to pharmaceutical compositions of dpp iv inhibitors with an amino group, their preparation and their use to treat diabetes mellitus.. .

Substituted naphthyridine and quinoline compounds as mao inhibitors

Wherein r1, r2, r3, y, and n have any of the values described herein and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies, detection and imaging techniques, and radioactive treatments; and therapies, including inhibiting mao, and mao-b selectively, enhancing neuronal plasticity, treating neurological disorders, providing neuroprotection, treating a cognitive impairment associated with a cns disorder, enhancing the efficiency of cognitive and motor training, providing neurorecovery and neurorehabilitation, enhancing the efficiency of non-human animal training protocols, and treating peripheral disorders (including obesity, diabetes, and cardiometabolic disorders) and their associated co-morbidities.. .

Interference rejection membranes comprising crosslinked poly(vinyl alcohol) matrices for implantable glucose sensors

Embodiments of the invention provide amperometric analyte sensors having optimized elements such as interference rejection membranes as well as methods for making and using such sensors. The amperometric analyte sensor apparatus comprises: a base layer; a conductive layer disposed on the base layer and comprising a working electrode; an interference rejection membrane disposed on an electroactive surface of the working electrode, wherein the interference rejection membrane comprises poly(vinyl alcohol) (pva) polymers crosslinked by an acid crosslinker, wherein the crosslinker is a dicarboxylic acid type monomer or a polymer comprising a carboxylic acid group; and an analyte sensing layer.

Yeast screens for treatment of human disease

Screening methods for identifying substances that provide therapeutic value for various diseases associated with protein misfolding are provided. Genetic and chemical screening methods are provided using a yeast system.
The University Of Chicago

Alk7 binding proteins and uses thereof

This disclosure provides alk7-binding proteins such as anti-alk7 antibodies, and compositions and methods for making the alk7-binding proteins. In certain embodiments the alk7-binding proteins inhibit, or antagonize alk7 activity.
Adimab, Llc

Methods for reducing cd36 expression

The invention provides a method for treating one or more complications of diabetes in a mammal. The method comprises administering to a mammal in need thereof an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3 pm is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1..
Cornell Research Foundation, Inc.

Pharmaceutical composition, methods for treating and uses thereof

The invention relates to a pharmaceutical composition according to the claim 1 comprising an sglt2 inhibitor and a glp-1 receptor agonist which is suitable in the treatment or prevention of diabetes mellitus, impaired glucose tolerance, hyperglycemia or other conditions. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions..
Boehringer Ingelheim International Gmbh

Composition and treating metabolic disorders

Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia and type 2 diabetes mellitus (t2dm) and/or, e.g., the treatment of other medical disorder(s) including immune or endocrine disorders or diseases. Bromocriptine citrate is administered over a limited or extended period at a time of day dependent on re-establishing the normal circadian rhythm of central dopaminergic activity of healthy members of a similar species and sex.
Veroscience Llc

Methods for treatment of disease using galvanic vestibular stimulation

Methods are provided for treating diseases by altering body mass composition in a human subject through application of galvanic vestibular stimulation (gvs) using electrodes placed in electrical contact with the subject's scalp at a location corresponding to each of the subject's left and right vestibular systems. The methods may be used to treat obesity-related diseases such as diabetes, hypertension, type 2 diabetes mellitus and osteoporosis.
The Regents Of The University Of California

Hydrogel prodrug for treatment

Aspects of the invention described herein include a hydrogel prodrug and methods of making a hydrogel prodrug for drug delivery. Also contemplated are methods of treating, inhibiting, ameliorating or inhibiting a disease or disorder.
Viking Scientific, Inc.

Method for treating hyperglycemia with glp-1

A method for treating hyperglycemia and/or diabetes in a subject is provided. In particular, the method is directed for the treatment of patients with type 2 diabetes mellitus who have a fasting blood glucose concentration greater than about 8 mm, wherein the patient is administered a formulation comprising a glp-1 molecule and a diketopiperazine by pulmonary inhalation with a dry powder inhalation system..
Mannkind Corporation

Use of low dose il-2 for treating autoimmune – related or inflammatory disorders

The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type i diabetes and other autoimmune and/or inflammatory diseases..
Universite Pierre Et Marie Curie (paris 6)

Methods for increasing the selective efficacy of gene therapy using car peptide and heparan sulfate mediated macropinocytosis

Disclosed are compositions and methods for triggering disease selective macropinocytosis. The compositions can serve as a marker of disease activity and as a trigger of enhanced macropinocytosis in tissues undergoing disease remodeling such as wound healing, cancer, pah, inflammation, diabetes, crohn's disease, ulcerative colitis, ankylosing spondylitis, diseases of the endometrium, psoriasis, irritable bowel syndrome, arthritis, fibrotic disorders, interstitial cystitis, autoimmune diseases, asthma, acute lung injury, and adult respiratory distress syndrome.
Vascular Biosciences

Selective nav1.7 inhibitors for the treatment of diabetes

Provided herein are methods for treating or preventing prediabetes or diabetes, or maintaining or lowering blood or plasma glucose or maintaining or lowering blood or plasma glycated hemoglobin comprising administering to a subject in need thereof a therapeutically effective amount of a compound selectively inhibiting nav1.7. In particular, provided herein are processes for the preparation of and intermediates used in the preparation of compounds selectively inhibiting nav 1.7, such as the compounds of formula i or compounds of formula i′:.
Chromocell Corporation

Sglt-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease

The present invention relates to certain sglt-2 inhibitors, such as ertugliflozin or a co-crystal or a pharmaceutically acceptable salt thereof, for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (ckd). The present invention also relates to methods for preventing neuronal damage following the incidence of ischemic stroke and close-head traumatic brain injury in animals comprising the step of administering to an animal, in need of such treatment, a therapeutically effective amount of ertugliflozin or a co-crystal or a pharmaceutically acceptable salt thereof..
Pfizer Inc.

Delicious garlic shakes and smoothies

These delicious shakes or smoothies, has the active compound called allicin, which comes from the garlic. Allicin is the key ingredient for helping to lower our metabolic risk factors.

Systems and methods for health management

Described herein are systems and methods of diabetes management and prediabetes prevention. The method includes rendering a graphical user interface including a first plurality of hexagonal tiles arranged in a honeycomb pattern, the first plurality of hexagonal tiles together displaying tracked data for a plurality of datatypes; receiving a tracked data input for a first datatype; adding the input data to a new or an existing hexagonal tile representing a tracked data point of the first datatype; dynamically rearranging the first'plurality of hexagonal tiles to maintain a time-ordered sequence of tracked data; receiving a user selection of a tile of a second datatype; and displaying a plurality of icons representing selectable user options corresponding to the user-selected tile.

Use of cd5 antigen-like as a biomarker for diabetic nephropathy

Biomarkers for pre-diabetes, diabetes and/or a diabetes related conditions, and methods of their use, including the biomarkers in tables 1 and 2 such as peroxiredoxin-2, complement c1q subcomponent subunit b, sulfhydryl oxidase 1 and apolipoprotein a-iv.. .

Phosphorylation of histones and uses thereof

Phosphorylation of histones was observed at certain tyrosine residues which have not been associated with epigenetic modification. These sites include h2b tyr37, h4 tyr88 and tyr 51 and h3 tyr99.

Modulators of ror-gamma receptors, composition and use thereof

The present invention provides novel methods to treat disease by modulating retinoid-related orphan receptor gamma (ror-gamma) in vitro and in vivo with ursolic acid analogs, and compositions thereof. The methods and compounds disclosed herein are useful for inhibiting the differentiation of a population of t cells, or treating a disease related to th17 cell responses in a subject.

Brain permeant peptidomimetic beta-secretase 1 inhibitors for the treatment or prophylaxis of neurological disorders or conditions

The present application presents novel peptidomimetic substituted hydroxyethylene compounds, which are inhibitors of beta amyloid cleavage enzyme, capable to permeate the brain and to achieve therapeutic concentrations in the target organ, the brain. These compounds are incorporated in pharmaceutical compositions and applied in the treatment or prophylaxis of neurological disorders or conditions and also other disorders or conditions including down's syndrome and diabetes..

Differentiation of pluripotent stem cells to intestinal midgut endoderm cells

Cell populations of intestinal midgut endoderm cells and methods of generating the cells expressing markers characteristic of intestinal endoderm lineage are disclosed. Methods of treating conditions such as diabetes are also disclosed..

Composite preparation, containing novel 3-(4--(benzyloxy)phenyl)hex-4-inoic acid derivative and another active ingredient, for preventing or treating metabolic diseases

The present invention relates to a pharmaceutical composition for preventing or treating metabolic diseases, in which a novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative and at least another active ingredient, which is selected from the group consisting of dipeptidyl peptidase-4 (dppiv) inhibitor-based, sulfonylurea-based, thiazolidinedione (tzd)-based, biguanide-based, and sodium/glucose cotransporter 2 (sglt2) inhibitor-based drugs, may be administered in combination or in the form of a composite preparation. The use of the composition of the present invention can provide a remarkably excellent blood sugar reducing effect in various animal diabetic disease models, and the composition of the present invention can be favorably used as a pharmaceutical composition for preventing or treating metabolic diseases, such as obesity, diabetes type i, diabetes type ii, glucose intolerance symptoms, insulin resistance symptoms, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia, and syndrome x..

Selective agonists of beta-adrenergic type 3 receptors (bar3) and use thereof

Object of the present invention is the use of selective agonists of beta-adrenergic type 3 receptors (bar3) in the treatment of nephrogenic diabetes insipidus (ndi), in particular of x-linked nephrogenic diabetes insipidus (x-ndi).. .

Improved sugar-depleted fruit or vegetable juice and juice-retaining fruit or vegetable derived matter, methods of producing the same and the use thereof to maintain health and to treat and prevent medical ailments

The present invention provides a sugar-depleted fruit or vegetable juice product, wherein said juice product is a fruit or vegetable juice or juice-retaining fruit or vegetable derived matter, wherein said juice product contains at least about 5 g/l gluconic acid and said juice product contains any two or three, of (i) at least about 0.5 g/l ca2+, (iii) at least about 1 g/l k+, and (iii) at least about 0.1 g/l mg2+. Also provided are methods of producing the same and the use thereof to assist in maintaining the health and well-being of a subject and in the treatment and prevention of medical ailments, specifically those associated with the over-consumption of glucose and/or sucrose or inappropriate metabolism of glucose, e.g.

Mapping sympathetic nerve distribution for renal ablation and catheters for same

This invention provides methods for mapping and ablating renal nerves to treat disease caused by systemic renal nerve hyperactivity, e.g. Hypertension, heart failure, renal failure and diabetes.

Proteins increasing pancreatic beta cell number and methods of use

Disclosed herein are bacterial proteins that increase pancreatic beta (β) cell number and/or proliferation, methods of increasing β cell number and/or proliferation using such proteins, and methods of treating or inhibiting diabetes in a subject by administering such proteins to the subject. In some embodiments, the protein has at least 80% sequence identity to the amino acid sequence set forth as any one of seq id nos: 1-7, or fragments thereof.
University Of Oregon

Growth differentiation factor 15 (gdf-15) polypeptides

Gdf15 polypeptides, constructs comprising gdf15, and mutants thereof are provided. In various embodiments the gdf15 polypeptides, constructs comprising gdf15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder.
Amgen Inc.

Substituted benzothiophenyl derivatives as gpr40 agonists for the treatment of type ii diabetes

Wherein u1, u2, u3, r1, r2, z, and w are defined herein.. .

Adeno-associated viral vectors for the gene therapy of metabolic diseases

The present invention discloses adeno-associated viral vectors useful in gene therapy methods for the treatment of obesity, insulin resistance, type 2 diabetes, liver cirrhosis and non-alcoholic fatty liver disease (nafld)/non-alcoholic steatohepatitis (nash). The invention also relates to polynucleotides, plasmids, vectors and methods for the production of such adeno-associated viral vectors.
Universitat Autonoma De Barcelona

Oral spray containing ixeris dentata nakai extract as active ingredient for preventing or treating xerostomia caused by diabetes

When the ixeris dentata nakai extract is administered using the formulation of the present invention, the ixeris dentata nakai extract is sublingually sprayed through the spray formulation, and thus can be directly locally administered to a salivary gland tissue having an activity to induce secretion of saliva. Therefore, saliva secretion can be induced by rapid absorption of the active ingredient of the ixeris dentata nakai extract in the salivary gland tissue without any absorption process through the digestive system, resulting in minimized side effects..

Method and composition for treatment or prevention of type 2 diabetes and hyperlipidemia

The present invention provides a method of treating or preventing type 2 diabetes and hyperlipidemia in a subject in need thereof, comprising administrating to the subject a therapeutically effective amount of a compound of formula i. The present invention also provides a pharmaceutical composition for treatment or prevention of type 2 diabetes and hyperlipidemia, comprising a compound of formula i and a pharmaceutically acceptable carrier.

Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with serm

Novel methods for prevention, reduction or elimination of the incidence of male androgen deficiency symptoms or diseases including male hypogonadism-associated symptoms and diseases associated with low serum testosterone and/or low dhea or low total androgens in susceptible warm-blooded animals including humans involving administration of an amount of a sex steroid precursor, particularly dehydroepiandrosterone (dhea) and a selective estrogen receptor modulator (serm) (particularly acolbifene), an antiestrogen or a prodrug of the two. The symptoms or diseases are loss of libido, erectile dysfunction, tiredness, loss of energy, depression, bone loss, muscle loss, muscle weakness, fat accumulation, memory loss, cognition loss, alzheimer's disease, dementia, loss of body hair, fertility problems, insomnia, gynecomastia, anemia, hot flushes, sweats, decreased sense of well-being, obesity, osteoporosis, hypercholesterolemia, hyperlipidemia, atherosclerosis, hypertension, insulin resistance, cardiovascular disease and type 2 diabetes.
Endorecherche, Inc.

Method of using dihydro-resveratrol or its stilbenoid derivatives and/or chemical variants in treatments of fibrotic and diabetic conditions

The present invention relates to a polyphenol derivative of the stilbenoid family, namely trans-3,5,4′-trihydroxybibenzyl, also known as dihydro-resveratrol, as a remedial agent. In particular, the present invention presents the usage of dihydro-resveratrol as an anti-fibrotic agent in suppressing the activation of pancreatic stellate cells (pscs).
Hong Kong Baptist University

Peptides having reduced toxicity that stimulate cholesterol efflux

The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., apo ai and apo e), and having high selectivity for abca1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses.
The Regents Of The University Of California

Compounds and methods for kinase modulation, and indications therefor

In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on one or more of fms, kit, flt3, trka, trkb and trkc kinase protein. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of one or more of fms, kit, flt3, trka, trkb and trkc, including rheumatoid arthritis, osteoarthritis, osteoporosis, peri-prosthetic osteolysis, systemic sclerosis, demyelinating disorders, multiple sclerosis, charcot marie tooth syndrome, amyotrophic lateral sclerosis, alzheimer's disease, parkinson's disease, global ischemia, ulcerative colitis, crohn's disease, immune thrombocytopenic purpura, atherosclerosis, systemic lupus erythematosis, myelopreparation for autologous transplantation, transplant rejection, glomerulonephritis, interstitial nephritis, lupus nephritis, tubular necrosis, diabetic nephropathy, renal hypertrophy, type i diabetes, acute pain, inflammatory pain, neuropathic pain, acute myeloid leukemia, melanoma, multiple myeloma, breast cancer, prostate cancer, pancreatic cancer, lung cancer, ovarian cancer, gliomas, glioblastoma, neurofibromatosis, osteolytic bone metastases, brain metastases, gastrointestinal stromal tumors, and giant cell tumors..

Indole derivatives for the prevention and/or treatment of diabetes and associated metabolic disorders

The invention relates to substituted heterocyclic indole derivatives of formula (i), which act as activators of the amp-activated protein kinase (ampk) and to the use of them for the treatment and prevention of diseases or disorders regulated by ampk. As a result, these compounds can be used for the treatment of inflammatory, autoimmune, cardiovascular, neurological diseases and cancer..
Centro De Investigacion Biomedica En Red (ciber)

Methods for treating and/or limiting development of diabetes in subjects with amyotrophic lateral sclerosis

Methods for treating and/or limiting development of diabetes in a subject with amyotrophic lateral sclerosis (als) by inhibiting igg-mediated activation of voltage-gated calcium channels (vgccs) in cells of the subject, by one or more of removing igg from blood of the subject, blocking igg from activating vgccs in the subject; or blocking vgccs in the subject are described, as are methods for identifying als patients at risk of developing diabetes.. .
Biocrine Ab

Multi-cbv vaccine for preventing or treating type i diabetes

The invention is directed to a vaccine comprising: i) coxsackie b virus cbv1 and cbv2, and ii) at least one coxsackie b virus selected from cbv3, cbv4, cbv5 and cbv6. The cbvs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus.
Vactech Oy

Peptide conjugates of glp-1 receptor agonists and gastrin and their use

The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes related diseases or disorders.. .
Zealand Pharma A/s

Pharmaceutical compositions and methods for the treatment of diabetes

This invention relates to compositions and methods for treating type i diabetes. Compositions of the invention include active compounds such as harmine, indy, or derivatives thereof to induce reproduction of beta cells.
University Of Limerick

Smart logging for management of health-related issues

A system managing health-related issues (e.g., diabetes) includes a measurement device to measure a health characteristic and a processing device communicatively coupled to the measurement device. The processing device receives the measurement from the measurement device.
Ascensia Diabetes Care Holdings Ag

Elisa for vegf

The vascular endothelial growth factor (vegf) activity in a patient's bloodstream or other biological sample can serve as a diagnostic and prognostic index for cancer, diabetes, heart conditions, and other pathologies. Antibody-sandwich elisa methods and kits for vegf as an antigen are provided to detect types of vegf levels in biological samples from animal models and human patients and can be used as a diagnostic/prognostic index..
Genentech, Inc.

Methods of preserving and protecting pancreatic beta cells and treating or preventing diabetes by inhibiting nox-1

Methods of preserving and/or protecting pancreatic beta cells by inhibiting nox-1. In a further aspect, nox-1 inhibitors are administered to a subject in order to preserve and/or protect beta cells in the prevention or treatment of diabetes.
Eastern Virginia Medical School

Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists

Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the gipr polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
Amgen Inc.

Isoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2

The present invention relates to a compound represented by formula i: and pharmaceutically acceptable salts thereof. The compounds of formula i are inhibitors of diacylglyceride o-acyltransferase 2 (“dgat2”) and may be useful in the treatment, prevention and suppression of diseases mediated by dgat2.
Merck Sharp & Dohme Corp.

Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferase

Compositions and methods are disclosed that relate to small molecule lipopeptidomimetic inhibitors of mammalian ghrelin o-acyl transferase (goat). Compounds of general formula (i) and substructures thereof, i.e., formulae (ii), (iia), (iia1), (iia2), (iib), (iib1), (iib2), (iic) and (iii), are shown to exhibit potent inhibition of the octanoylation of ghrelin peptide, where the resulting non-octanoylated (des-acyl) form of ghrelin lacks ghsr ligand activity that is associated with weight gain and insulin resistance.
The Regents Of The University Of California

Novel antagonists of the glucagon receptor

The present invention provides for novel compounds of formula (i) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including type i and ii diabetes, insulin resistance and hyperglycemia.
Metabasis Therapeutics, Inc.

Polymeric stabilizing formulations

The present invention provides compositions of a therapeutic agent and a polymeric stabilizing agent for stabilizing the reservoir of an implantable drug delivery system. The present invention also includes an implantable drug delivery system incorporating the composition of the present invention, as well as methods of treating diabetes using the compositions and implantable drug delivery system of the present invention..
Nano Precision Medical, Inc.

Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2

The present invention relates to a compound represented by formula i:and pharmaceutically acceptable salts thereof. The compounds of formula i are inhibitors of diacylglyceride o-acyltransferase 2 (“dgat2”) and may be useful in the treatment, prevention and suppression of diseases mediated by dgat2.
Merck Sharp & Dohme Corp.

Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2

The present invention relates to a compound represented by formula (i): and pharmaceutically acceptable salts thereof. The compounds of formula (i) are inhibitors of diacylglyceride o-acyltransferase 2 (“dgat2”) and may be useful in the treatment, prevention and suppression of diseases mediated by dgat2.
Merck Sharp & Dohme Corp.

Use of flavonoids in manufacturing compositions for wound healing

Disclosed is a method for wound healing comprising administering a subject in need thereof a therapeutically effective amount of a flavonoid compound, wherein the compound is preferably nonglycosylated flavone. Specifically, the present invention can be used for treating skin symptoms of a trauma, a burn, a scald and a chronic wound, and can be particularly used for healing a wound of a diabetes patient..
Oneness Biotech Co., Ltd

Thermometer device

A device for measuring the temperature of a lower extremity of a subject in need of such monitoring. The device is especially suited for monitoring the foot temperature of a subject with diabetes or another condition that could lead to lower blood circulation and temperature in the lower extremities of the subject.
Jackson State University

Prodrug of 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline

The present invention relates to the compound (2r,2′r)-bis(((((tetrahydro-2h-pyran-4-yl)oxy)carbonyl)oxy)methyl) 1,1′-adipoylbis(pyrrolidine-2-carboxylate), pharmaceutical compositions comprising the same and the use of the same for treatment of diseases or disorders wherein depletion of serum amyloid p component (sap) would be beneficial, including amyloidosis, alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.. .
Glaxosmithkline Intellectual Property Development Limited

Negative hydrogen ion intellegrnt filtration system for curing cancer, cardiovascular disease, diabetes, hypertension, nephrotic syndrome, gout, dysautonomia and atopic dermatitis

A negative hydrogen ion intelligent filtration system includes a housing; a filtering mechanism disposed in the housing and comprising a first filter, a second filter connected to the first filter, a third filter connected to second filter, a fourth filter connected to the third filter, a fifth filter connected to the fourth filter, a sixth filter connected to the fifth filter, a seventh filter connected to the sixth filter, an eighth filter connected to the seventh filter, a ninth filter connected to the eighth filter, a tenth filter connected to the ninth filter, a eleventh filter connected to the tenth filter and a twelfth filter connected to the eleventh filter; an inflow port connected to the first filter and extending out of the housing; an outflow port connected to the twelfth filter and extending out of the housing; and a flow rate control mechanism disposed in the housing, located between the first filter and the inflow port and connecting the first filter and the inflow port.. .
Mega Sun Biomedical Corp.

Compositions and methods for producing elevated and sustained ketosis

Beta-hydroxybutyrate mineral salts in combination with medium chain fatty acids or an ester thereof such as medium chain triglycerides were used to induce ketosis, achieving blood ketone levels of (2-7 mmol/l), with or without dietary restriction. The combination results in substantial improvements in metabolic biomarkers related to insulin resistance, diabetes, weight loss, and physical performance in a short period of time.
University Of South Florida

Compositions and methods for diagnosis and treatment of metabolic syndrome

Compositions including an odd chain fatty acid, and salts and derivatives thereof, and methods for metabolic syndrome treatment and prophylaxis are provided, including compositions and methods for treating diabetes, obesity, hyperferritinemia, elevated insulin, glucose intolerance, dyslipidemia and related conditions. Methods for the diagnosis and monitoring of metabolic syndrome are also provided..
United States Of America, As Represented By The Secretary Of The Navy

Diabetes testing kit and methods for its use

Methods and apparatuses for use in screening for and assessing neuropathies, such as severe diabetic neuropathies of the feet, also known as loss of protective sensation (“lops”). The methods and apparatuses described herein employ a kit including one or more of an insert having at least one testing instrument attached thereto, the at least one testing instrument comprising at least a holder and a monofilament; an enclosure including inner compartments for holding and securing the insert; a folder having one or more pockets for securing the insert and one or more of a mirror, a packet and other material, such as instructions.
Medical Monofilament Manufacturing Llc

Process for preparation of a grifola frondosa polysaccharide f2 and its hypoglycemic activity

A grifola frondosa polysaccharide f2 with hypoglycemic activity, process for preparation and use thereof. The process for preparation of grifola frondosa polysaccharide f2 is as follows: the fruit bodies of grifola frondosa were homogenized to a fine powder and extracted with hot water.
Guangdong Yuewei Edible Fungi Technology Co.,ltd.

Stabilized insulinotropic peptides and methods of use

The present invention provides stably crosslinked insulinotropic polypeptides having superior and unexpected benefits in the treatment of conditions involving abnormal glucose homeostasis, e.g., type 2 diabetes and conditions relating to type 2 diabetes. Such benefits include, but are not limited to, extended polypeptide half-life, enhanced alpha-helicity, improved thermal stability and protease resistance, increased functional activity and pharmacologic properties, improved bioavailability when administered by any route, and improved bioavailability and gastrointestinal absorption when delivered orally, as compared to the corresponding unmodified polypeptides.
Dana-farber Cancer Institute, Inc.

Treatment of diabetes, toll-like receptor 4 modulators and methods for using the same

The present invention relates to treatment of diabetes, toll-like receptor 4 (tlr-4) modulators and methods for using the same. Particularly, the present invention provides an isolated peptide from pneumolysin (ply peptide) which is effective in treatment of diabetes.
Kemyth Biotech Co., Ltd.

Fgf-8 for use in treating diseases or disorders of energy homeostasis

The present invention relates to polypeptides for use in treating diseases or disorders of energy homeostasis such as obesity, dyslipidemia, diabetes, insulin resistance, hyperglycemia or the metabolic syndrome. The invention also relates to polynucleotides encoding said polypeptides for use in treating diseases or disorders of energy homeostasis.
Technische Universität München

Amine polymers for use as bile acid sequestrants

The present invention provides crosslinked amine polymers effective for binding and removing bile salts from the gastrointestinal tract. These bile acid binding polymers or pharmaceutical compositions thereof can be administered to subjects to treat various conditions, including hypercholesteremia, diabetes, pruritus, irritable bowel syndrome-diarrhea (ibs-d), bile acid malabsorption, and the like..
Relypsa, Inc.

Corticosteroid formulations and methods for the treatment of joint pain in patients with diabetes

This invention relates to the use of corticosteroids in patients with diabetes, including patients with type 2 diabetes, to treat pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis without increasing or otherwise significantly impacting blood glucose concentrations in diabetic patients, and to slow, arrest or reverse structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or periarticular tissues caused by osteoarthritis or rheumatoid arthritis without increasing or otherwise impacting blood glucose concentrations. More specifically, a formulation of triamcinolone acetonide (tca) is administered locally to diabetes patients, including type 2 diabetes patients, as a sustained release dosage form (with or without an immediate release component) that results in efficacy levels accompanied by clinically insignificant or no measurable effect on blood glucose levels..
Flexion Therapeutics, Inc.

Fatty acid cysteamine conjugates and their use as activators of autophagy

The invention relates to (i) 6-membered heteroaryl substituted fatty acid cystamine conjugates, compositions thereof, methods of treating diseases involving dysregulation of autophagy, such as cystic fibrosis, idiopathic pulmonary fibrosis (ipf), a neurodegenerative disease, inflammatory disease, liver disease, muscle disease, infection and immune disease with this compound, or (ii) a method of treating idiopathic pulmonary fibrosis, mitochondrial diseases, leigh syndrome, diabetes mellitus and deafness (dad), leber's hereditary optic neuropathy, neuropathy-ataxia-retinis pigmentosa and ptosis (narp), myoneurogenic gastrointestinal encephalopathy (mng1e), myoclonic epilepsy with ragged red fibers (merrf), or mitochondrial myopathy-encephalomy-opathy-lactic acidosis stroke like symptoms (melas), comprising administering to a patient the fatty acid cysteamine conjugate, (4z, 7z. 10z, 13z, 16z, 19z)—n-(2-mercaptoethyl) docosa-4,7,10,13,16,19-hexaenamide or (5z, 8z, 11z, 14z, 17z)—n-(2-mercaptoethyl) icosa-5,8,11,14,17-pentaenamide..
Catabasis Pharmaceuticals, Inc.

Diabetes control using postprandial feedback

Disclosed is a postprandial glucose-measuring device for preventing the development of or reversing t2d. Included are methods for using the device as well as better use for invasive and noninvasive glucose meters.

Rapid screening and evaluation of diabetes and prediabetes by glycated hemoglobin mass spectrometry

The method describes rapid screening of whole blood samples, pin prick and blood spot cards, subjected to maldi-tof mass spectrometry. The spectra is generated and compared to those from normal healthy controls.
Map Ip Holding Limited

Method for detecting and purifying pancreatic beta cells

The invention is based, in part, on the discovery that a polypeptide, referred to herein as betacam, is selectively expressed on the surface of pancreatic islet cells. Thus, in one aspect, the invention is directed to compositions comprising betacam or that can be used to detect betacam.
The Regent Of The University Of Colorado, A Body Corporate

Method for screening drug-saccharide conjugates

Methods for identifying drug-saccharide conjugates that bind the mannose receptor, c type 1, (mrc1) and may be taken up by cells expressing mrc1, and the use of such drug-saccharide conjugates for treatment of particular diseases are described. In particular, the methods for identifying insulin-saccharide conjugates that bind the mrc1 receptor and may be taken up by cells expressing the mrc1 and use of such conjugates for treatment of diabetes are described..
Merck Sharp & Dohme Corp.

2-alkyloxy benzene formyl arylamine compound and pharmaceutical use thereof

2-alkoxy benzene formyl arylamine compounds and their pharmaceutical salts are disclosed. The compounds can act as sphingomyelin synthase (sms) inhibitors to treat diseases caused by abnormal increasing of sphingomyelin (sm).
Fudan University

Probability based controller gain

Methods and systems are disclosed for estimating a glucose level of a person having diabetes and selecting automatically open-loop and closed-loop control for a connected therapy delivery device. The method may comprise analyzing measured glucose results and corresponding impedance values received from a glucose sensor coupled to the person with a probability analysis tool implemented by a microcontroller to determine a total quality score that is based on the minimum constraint of a probability of glucose sensor accuracy determined measured glucose results and a probability of sensing quality determined from the impedance values.
Roche Diabetes Care, Inc.

Compounds against ralstonia pickettii for use in the treatment of insulin resistance, and diagnosis of insulin resistance

Compounds disclosed herein are effective against ralstonia pickettii for treating or preventing insulin resistance, obesity or type ii diabetes of a subject, and include an antibiotic effective against ralstonia pickettii, an immunogenic compound producing a protective immune response, or an antibody which specifically binds to ralstonia pickettii or a fragment thereof. In vitro methods for diagnosis or prediction of insulin resistance, obesity or type ii diabetes include determining the presence of ralstonia pickettii or of an antibody which specifically binds to ralstonia pickettii in a test sample.
Wageningen Universiteit

Extract of toona sinensis from supercritical fluid extraction for treating diabetes and metabolic disease, the preparation method and the use thereof

The toona sinensis extract of the present invention is prepared using supercritical fluid technique, wherein the method includes steps of: (a) drying the leaves of t. Sinensis; (b) pulverizing the leaves as particles; and (c) extracting the particles with supercritical carbon dioxide to obtain the t.
Kaohsiung Medical University

Probiotic bifidobacterium adolescentis strains

The present invention relates to novel isolated strains of bifidobacterium adolescentis which are capable of i) increasing the trans-epithelial electrical resistance (ter) of a caco-2 cell monolayer after 10 h treatment to more than 120% of ter at treatment start, ii) inducing secretion of >200 pg/ml of il-10, and/or iii) inducing an il-10:il-12 ratio>1 when co-incubated with human pbmc derived dendritic cells. The strains may have one, two or all three of these capabilities.
Chr. Hansen A/s

Patient diabetes monitoring system with clustering of unsupervised daily cgm profiles (or insulin profiles) and method thereof

A patient diabetes monitoring system with an efficient unsupervised daily monitoring profile clustering algorithm, a method, and a computer product thereof are disclosed. The system may include a physiological data input device or sensor which receives a plurality of physiological measurements to generate a dataset, a memory which stores a clustering algorithm, and a processor.
Roche Diabetes Care, Inc.

Method for screening drug-saccharide conjugates

Methods for identifying drug-saccharide conjugates that bind the mannose receptor, c type 1, (mrc1) and may be taken up by cells expressing mrc1, and the use of such drug-saccharide conjugates for treatment of particular diseases are described. In particular, the methods for identifying insulin-saccharide conjugates that bind the mrc1 receptor and may be taken up by cells expressing the mrc1 and use of such conjugates for treatment of diabetes are described..
Merck Sharp & Dohme Corp.

Anti-tnf antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes

The present invention relates to compositions and methods utilizing anti-tnf antibodies having a heavy chain (hc) comprising seq id no:36 and a light chain (lc) comprising seq id no:37 for use in the treatment or prevention of type i diabetes (t1d).. .
Janssen Biotech, Inc.

Metformin derivatives

The present invention relates to novel biguanide derivatives including their pharmaceutically acceptable salts. The invention also relates processes for the preparation of, intermediates used in the preparation of, pharmaceutical compositions containing and the uses of such compounds in treating disorders such as diabetes..
Biopharma Works Llc

Novel amino-phenyl-sulfonyl-acetate derivatives and use thereof

The present invention relates to a novel amino-phenyl-sulfonyl-acetate derivative or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating diabetes comprising the same as an active ingredient.. .
Cj Healthcare Corporation



Diabetes topics:
  • Immune Disorder
  • Autoimmune
  • Immune Disease
  • Immune Diseases
  • Autoimmune Disorder
  • Type 1 Diabetes
  • Autoimmune Disorders
  • Vascular Diseases
  • Antimicrobial
  • Cardiovascular
  • Inflammatory Disease
  • Antimicrobial Agent
  • Stem Cells
  • Human Embryonic Stem Cell
  • Embryonic Stem Cell


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Diabetes for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Diabetes with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.4451

    file did exist - 12269

    2 - 1 - 254